Doing Two Jobs Badly: The Burnout Cost of Asking Scientists to Be Their Own Marketing Departments

A neurotechnology researcher at a Spanish university founded a spinout in 2020 around a brain-computer interface platform with applications in post-stroke rehabilitation. For the first eighteen months, she maintained her full academic role — teaching, supervising doctoral students, serving on grant review panels, submitting a major ERC application — while simultaneously managing investor relations, overseeing the company's website and LinkedIn presence, preparing pitch materials, attending startup events, answering due diligence requests, and negotiating a pilot agreement with a rehabilitation clinic. She did not take a holiday. She averaged, by her own estimate, sixty-eight working hours per week. In the spring of 2022, she collapsed during a conference presentation — not dramatically, but unmistakably: she lost her thread, lost her composure, and stood at the podium for several seconds unable to recall the next word of a talk she had given seven times. Her doctor diagnosed exhaustion. Her cardiologist found elevated stress markers. She took six weeks of medical leave. The spinout lost momentum it never fully recovered. "I was trying to be two people," she said afterward. "Neither of those people was getting my best. Both of them were getting what was left."

Her experience is not unusual, and it is not primarily a story of poor personal planning or inadequate resilience. It is a story of a structural demand that has been placed on researcher-founders without any serious institutional acknowledgement that the demand is unreasonable — that the expectation of maintaining scientific excellence while simultaneously building the commercial infrastructure of a startup is not a high bar to clear but an impossible one, and that the burnout it produces is not a personal failure but a predictable system output.

The origins of the dual-role expectation are embedded in the commercialization mandates of the 1980s and 1990s that this series has traced across multiple articles. When governments and funding bodies began requiring universities to generate commercial impact from publicly funded research, the implicit model was of the scientist-entrepreneur: the researcher who would move fluidly between laboratory and boardroom, embodying both the intellectual depth of academic science and the commercial agility of a startup founder. This model had genuine exemplars — researchers who had built companies and maintained scientific reputations simultaneously — and those exemplars became the template against which all researcher-founders were implicitly measured.

What the model obscured was the selection effect at work in its exemplars. The researchers who successfully combined active science with company-building in the 1980s and 1990s typically had either exceptional personal resources — energy, support structures, financial cushion — or had made quiet choices that the model did not acknowledge: reduced laboratory output during the commercialization phase, delegation of scientific supervision to senior postdocs, strategic reduction of teaching commitments, or simply the acceptance of a sustained period of overwork that was survivable at thirty-five and would not have been at fifty. The model celebrated the outcome without examining the cost. The cost, distributed across a generation of researcher-founders who followed it, was significant.

The specific demands of the commercial role have also intensified dramatically since the original scientist-entrepreneur model was formed. In the 1990s, building a company's commercial presence meant attending trade shows, developing a brochure, and making phone calls. In 2025, it means maintaining a professional website that meets current investor expectations, managing a LinkedIn presence that establishes thought leadership in a competitive attention landscape, producing content that positions the company in its sector, responding to inbound due diligence requests that arrive with tight turnarounds, and managing a social media presence across multiple platforms — all of which requires specialist skills that did not exist as distinct professional disciplines when the dual-role expectation was established, and all of which competes directly with the time and cognitive bandwidth that the scientific role requires.

The cognitive dimension of the dual role deserves particular attention, because it is less visible than the time dimension but equally destructive. Scientific work — particularly the kind of deep, focused, generative thinking that produces genuine advances — requires extended periods of uninterrupted concentration. Cognitive scientists refer to this as "deep work" capacity: the ability to engage with complex problems at the level of abstraction that produces insight rather than merely competent execution. This capacity is finite within any given day, it degrades under sustained stress, and it is disproportionately damaged by the kind of context-switching that commercial activity imposes. The researcher who spends a morning in investor email correspondence, a lunchtime on LinkedIn content, and an afternoon in a legal negotiation call does not arrive at the next morning's laboratory session with their scientific thinking capacity intact. They arrive depleted — in ways they may not immediately attribute to the previous day's commercial demands but that accumulate, across weeks and months, into a measurable reduction in the quality and originality of their scientific output.

The scientific loss is not only personal. When a researcher-founder's scientific output declines during the commercialization phase — as the evidence consistently shows it does — the institution loses scientific productivity it was funding, the academic field loses a contributor operating at reduced capacity, and the spinout itself loses the one asset that no commercial hire can replace: the founder's ongoing scientific judgment about the technology's development direction. The most common failure mode of deep-tech spinouts is not commercial mismanagement. It is the gradual disconnection of the founding scientist from active scientific decision-making as the commercial demands of the company consume the time and attention that scientific leadership requires. The company that loses this connection tends to make development decisions that are commercially logical and scientifically suboptimal — optimizing for near-term investability rather than long-term technical advantage and arriving at the next funding round with a product that is further from the science and closer to the market in ways that have diminished rather than enhanced its fundamental value.

The wellbeing cost is the one that receives the least institutional attention and carries the most personal weight. Burnout in researcher-founders presents differently from burnout in other professional contexts because it arrives in people who have chosen, deliberately and with considerable personal investment, to pursue something they believe in. The erosion of motivation, the emotional exhaustion, the cynicism that characterizes clinical burnout does not feel like a response to external pressure in people who are doing work they care about. It feels, characteristically, like personal failure — the conclusion that they were not tough enough, not organized enough, not entrepreneurial enough to sustain both roles. This misattribution is itself a product of the system's failure to acknowledge the structural unreasonableness of what it is asking. The researcher is not failing the dual role. The dual role was always going to fail the researcher.

The division of labour that this situation calls for is not complicated to state, though it has been remarkably slow to arrive as a structural norm in the university innovation ecosystem. Scientists should do science. The communication, marketing, and commercial narrative work that surrounds a spinout — the website, the social media presence, the pitch deck, the investor communications, the content strategy, the brand positioning — should be done by people who are specifically trained for it, whose entire professional attention is available for it, and who can do it to a standard that a researcher dividing their attention between two full-time roles simply cannot match.

This is not a counsel of limitation. It is a counsel of excellence in the correct domain. The surgeon who is also expected to manage the hospital's marketing budget is not a more capable surgeon for the addition. They are a less capable one, whose surgical excellence is being diluted by a demand that a marketing professional could meet better, faster, and without any cost to the operating theatre. The researcher who is also expected to manage their spinout's LinkedIn strategy, write investor update emails, maintain a website, and develop content for a sector-specific audience is not a more capable scientist-entrepreneur for the attempt. They are a less capable scientist, doing marketing work at a level that a dedicated communication professional would exceed — and paying for the attempt with the scientific capacity that no one else in the company can supply.

An agency that takes the communication and marketing work entirely off the researcher's desk — building and managing the digital presence, producing the investor-facing content, maintaining the narrative momentum of the company's commercial story — does not merely save the researcher time. It restores the conditions under which genuine scientific work is possible. It gives back the uninterrupted mornings, the quiet space for the kind of thinking that produces ideas, and the cognitive depth that is the researcher's irreplaceable contribution to everything the company is trying to build. You do the research. Someone else handles the rest. That division is not a luxury. For the work to be worth doing, it is a necessity.